41 results
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
program, with gross proceeds of approximately $4.4 million.
R&D Expenses:
Research and development expenses for the three months ended March 31, 2024 … )
OPERATING EXPENSES
Research and Development
General and Administrative
TOTAL OPERATING EXPENSES
NET LOSS
LOSS PER SHARE
Basic and diluted net loss
FWP
ACXP
Acurx Pharmaceuticals Inc
2 Apr 24
Free writing prospectus
7:31am
to, clinical trials, research and development activities, acquisitions and collaborations. Securities Offered Common Stock
&UHDWHGE\%(-281
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
18 Mar 24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:15pm
Expenses:
Research and development expenses for the three months ended December 31, 2023 were $1.9 million compared to $1.4 million for the three months … December 31, 2023, research and development expenses were $6.0 million versus $4.8 million for the year ended December 31, 2022. The increase is due
424B5
zo8sxtd7jmw bey
15 Nov 23
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
tzb81vmxvsdgykq
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
8-K
EX-99.1
vqvqafvnulf
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am
424B3
u7ahi szio8ug19
13 Jul 23
Prospectus supplement
4:32pm
424B5
j51n6e nno
17 May 23
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
dnnms4fi6a1735xeotl
14 Nov 22
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
7:11am
424B3
fkl3n
23 Sep 22
Prospectus supplement
8:19am